{
    "clinical_study": {
        "@rank": "60482", 
        "acronym": "PTAD GIA", 
        "arm_group": [
            {
                "arm_group_label": "Interpersonal Psychotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression."
            }, 
            {
                "arm_group_label": "Fluoxetine", 
                "arm_group_type": "Other", 
                "description": "The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. The medication will be taken as a daily pill."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is:\n\n        1. To find out how long teenagers getting talk therapy (interpersonal psychotherapy) for\n           depression should get therapy before the therapist decides whether or not the teenager\n           is improving enough, and\n\n        2. To compare two ways of providing treatment to teenagers who have not improved enough."
        }, 
        "brief_title": "An Adaptive Treatment Strategy for Adolescent Depression-Continuation", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Adolescent Depression", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a continuation of the study \"An Adaptive Treatment Strategy for Adolescent\n      Depression (PTAD) \""
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adolescent meets DSM-IV-TR criteria for a diagnosis of Major Depressive Disorder,\n             Dysthymia, or Depressive Disorder NOS; demonstrate symptoms of depression (CDRS-R >\n             35); and demonstrate impairment in general functioning (CGAS < 65).\n\n          -  Adolescents and parents must be English-speaking\n\n        Exclusion Criteria:\n\n          -  Adolescent meets criteria for a diagnosis of Schizophrenia, Bipolar Disorder,\n             Psychosis, Substance Abuse, OCD, Conduct Disorder, Eating Disorder, PDD, or Mental\n             Retardation.\n\n          -  Depressed adolescents who are actively suicidal with a plan and/or intent\n\n          -  Adolescent that are already receiving treatment for depression or if they are taking\n             medication for a psychiatric diagnosis other than ADHD. Depressed adolescents with a\n             comorbid diagnosis of ADHD who are on a stable dose of stimulant medication (> 3\n             months) will be eligible to participate in the studies.\n\n          -  Adolescent that have already received an adequate trial of IPT-A or fluoxetine.\n\n          -  Female adolescents who are pregnant, breastfeeding, or having unprotected sexual\n             intercourse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017535", 
            "org_study_id": "1206M15365"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fluoxetine", 
                "description": "Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter.", 
                "intervention_name": "Fluoxetine", 
                "intervention_type": "Drug", 
                "other_name": "Prozac"
            }, 
            {
                "arm_group_label": [
                    "Interpersonal Psychotherapy", 
                    "Fluoxetine"
                ], 
                "description": "Adolescent randomized to an increase in therapy (4 extra therapy sessions)", 
                "intervention_name": "Interpersonal Psychotherapy", 
                "intervention_type": "Behavioral", 
                "other_name": "IPT"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fluoxetine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55454"
                }, 
                "name": "University of Minnesota, Department of Psychiatry"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Personalized Approach to Achieving a Sustained Response to Treatment for Adolescent Depression", 
        "overall_contact": {
            "email": "bortn005@umn.edu", 
            "last_name": "Ana Westervelt, BA", 
            "phone": "6126267065"
        }, 
        "overall_contact_backup": {
            "email": "houri005@umn.edu", 
            "last_name": "Alaa Houri, BS", 
            "phone": "6126267886"
        }, 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Meredith Gunlicks-Stoessel, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Clinician-administered semi-structured interview designed to assess present episode and lifetime history of psychiatric diagnoses based on DSM-IV criteria.", 
                "measure": "K-SADS-PL - baseline; change from baseline in KSADS at week 16 and 32", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "A self-report measure that assesses the severity of 21 depressive symptoms reflective of DSM-IV diagnostic criteria over the prior week.", 
                "measure": "BDI-II-baseline; change from baseline in BDI at weeks 4/8/12/16/24/32", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "A clinician-administered semi-structured interview measure developed to assess the severity of depression symptoms. It was initially designed for use with adults, but is widely used with adolescents, as well. It will also be used by the study clinicians in the first and fourth therapy sessions to guide implementation of the adaptive treatment strategy.", 
                "measure": "HRSD-baseline; change from baseline in HRSD at weeks 4/8/12/16/24/32", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "A clinician-administered standardized suicidal rating system that is based on definitions of suicidality derived from empirical findings on the phenomenology of suicidality and identified predictive and risk factors.", 
                "measure": "CSSR-S-baseline; change from baseline in CSSR-S at weeks 4/8/12/16/24/32", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017535"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Minnesota - Clinical and Translational Science Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Minnesota - Grant-in-Aid of Research, Artistry, &  Scholarship", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}